Search Results

You are looking at 1 - 10 of 67 items for :

  • "Brain metastasis" x
  • Refine by Access: All x
Clear All
Full access

Ritesh R. Kotecha, Ronan Flippot, Taylor Nortman, Annalisa Guida, Sujata Patil, Bernard Escudier, Robert J. Motzer, Laurence Albiges, and Martin H. Voss

Background Brain metastases are a critical site of disease progression in patients with metastatic renal cell carcinoma (mRCC). Large institutional and population-based studies estimate the incidence of brain metastasis to be 5% to 20%, 1

Full access

Matthew G. Ewend, David E. Morris, Lisa A. Carey, Alim M. Ladha, and Steven Brem

single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control . Clin Cancer Res 2007 ; 13 : 3637 – 3641 . 5. Markesbery WR Brooks WH Gupta GD . Treatment

Full access

Joe Y. Chang and Vivek Verma

/mediastinal lymph node involvement, a PD-L1 expression of 10%, and no driver mutations. He presented with a symptomatic isolated brain metastasis and underwent surgical resection, followed by radiosurgery (15 Gy). He was treated using carboplatin/pemetrexed for 4

Full access

Belqis El Ferjani, Sheenu Chandwani, Meita Hirschmann, Seydeh Dibaj, Emily Roarty, Jianjun Zhang, Waree Rinsurnogkawong, Jeff Lewis, Jack Lee, Jack A. Roth, Stephen Swisher, John V. Heymach, Thomas Burke, and George R. Simon

stage IV diagnosis, 87.2% with nonsquamous histology, 36.1% with bone metastasis, 29.4% with brain metastasis, 43.2% with 0–1 performance status, and 21.6% with a known EGFR or ALK mutation. A total of 233 pts had been tested for PD-L1 (78

Full access

Marina Deuker, Giuseppe Rosiello, Lara Franziska Stolzenbach, Thomas Martin, Claudia Collà Ruvolo, Luigi Nocera, Zhe Tian, Frederik C. Roos, Andreas Becker, Luis A. Kluth, Derya Tilki, Shahrokh F. Shariat, Fred Saad, Felix K.H. Chun, and Pierre I. Karakiewicz

. Location of Metastases According to Age and Sex Increasing age was associated with decreasing rates of brain metastasis in men (from 6.5% to 2.9%; P =.03) and women (from 5.9% to 0.7%; P =.01) ( Table 1 ). In women, increasing age was associated with

Full access

Michael G. Milligan, Angel M. Cronin, Yolonda Colson, Kenneth Kehl, Debra N. Yeboa, Deborah Schrag, and Aileen B. Chen

readily available than MRI+ while still being able to identify brain metastases in most patients. 22 , 24 Furthermore, use of MRI+ for brain metastasis screening in patients with potentially operable NSCLC does not impart a survival advantage over CT

Full access

Lilian Hanna, Gordon Taylor Moffat, Wilma Hopman, Pierre-Olivier Gaudreau, and Andrea S. Fung

the ED group 27% vs. 10% in the SD group. The pattern of recurrence in the ED group had a predilection for brain metastasis, with 33% compared to 5% in the SD group (p=0.064). Despite this, 93% of patients were alive in the ED group vs. 80% in the SD

Full access

Hassaan Raza Jafri, Isna Batool Khan, Ahmad Abu-Hashyeh, Vivek Yadala, Hassaan Yasin, Todd Gress, and Maria Tirona

at 6 months was determined as the end point. Factors analyzed included age at treatment, gender, body mass index, smoking status, comorbidities, pain before and after treatment, accompanying brain metastasis, single versus multiple sites of vertebral

Full access

Thomas Kaley and Louis B. Nabors

metastases, including solitary metastasis. Radiation is used as upfront therapy for local control, as an adjunct to surgery delivered to the surgical cavity, and as a boost to maximize local control. “The majority of patients with brain metastasis will have

Full access

Junji Lin, Santosh Gautam, Nan Hu, Debra Wertz, Gboyega Adeboyeje, and Sumesh Kachroo

(range 38.5-86.0 years). At diagnosis, 331 (81.5%) pts had extensive stage disease and 225 (55.4%) had brain metastasis. Of 346 pts with systemic treatment (IO-naïve) in 1st line (1L), 43 (12.4%) had impaired performance status. 255 (73.7%) used